Insulin Family intermediate
Insulin Glargine/Lixisenatide Fixed Ratio
Fixed-ratio combination of basal insulin glargine and rapid-acting GLP-1 agonist lixisenatide.
By Encyclopeptide Editorial | 1 min read
insulin glargine lixisenatide combination diabetes
Chemical Identity
| Property | Value |
|---|---|
| Product Name | Soliqua/Suliqua |
| Components | Insulin glargine + Lixisenatide |
| Route | Subcutaneous |
Clinical Applications
Indicated for type 2 diabetes when metformin alone is insufficient. Provides glycemic control comparable to basal-bolus regimens with lower hypoglycemia risk.
Biological Significance
This molecule plays important roles in biological systems and has potential therapeutic applications.
References
- Encyclopeptide Database. “Insulin Glargine/Lixisenatide Fixed Ratio” monograph. encyclopeptide.com.
Test Your Knowledge
Reinforce what you learned about Insulin Glargine/Lixisenatide Fixed Ratio with interactive quizzes on Wikipept.
Take a Quiz on Wikipept